论文部分内容阅读
最近,作为慢性浅表性/非萎缩性胃炎一线选择的新药——洛赛克10mg(奥美拉唑)在中国各地全面上市。它是由阿斯利康公司(AstraZeneca)在中国市场上推出的胃食管反流病维持治疗的首选用药。 中国是消化疾病的高发地区,作为国家教委重点学科的上海第二医科大学附属仁济医院消化科和上海市消化疾病研究所,深感只有加强国际间的学术交流,互相切磋,学习国外先进的科技知识,展示我国在该学科取得的工作成果,取长补短,才能提高医学水平及该学科在国内外的学术地位。为了提高治疗消化疾病的医疗水平,加强该领域国际
Recently, Losec 10mg (omeprazole), a new drug of choice for first-line chronic superficial / non-atrophic gastritis, is available in various markets across China. It is the drug of choice for maintenance treatment of gastroesophageal reflux disease by AstraZeneca in the Chinese market. China is a high incidence of digestive diseases. As the key discipline of the State Education Commission, Department of Gastroenterology, Renji Hospital, Shanghai Second Medical University, and Shanghai Institute of Digestive Diseases, it is only by deepening international academic exchanges, learning from each other and learning from advanced foreign countries Science and technology to showcase the achievements made by our country in this discipline and learn from each other’s strengths in order to improve the medical standards and the academic status of the discipline at home and abroad. In order to improve the medical treatment of digestive diseases, strengthen the international community